Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol
etabonate (LE), designed for ocular applications, resulting in the August 2018FDA approval of INVELTYS for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.
Food and Drug Administration (FDA) approved LOTEMAX[R] SM (loteprednol
etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery, and LOTEMAX[R] SM 0.38% has now launched
KPI-121 0.25% utilizes Kala's AMPPLIFY mucus-penetrating particle Drug Delivery Technology to enhance penetration of loteprednol
etabonate into target tissue of the eye.
The pseudomembrane was debrided and sent for culture, and the patient was prescribed oral amoxicillin clavulanate and moxifloxacin eye drops, with topical loteprednol
and cyclosporine to decrease the robust inflammatory response.
ALSO HIGHER: Akorn (AKRX) up 12.6% after getting FDA approval for Loteprednol
He adds that the Food and Drug Administration has recently granted approval of LOTEMAX SM (loteprednol
eta-bonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery.
Bausch + Lomb reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for LOTEMAX SM (loteprednol
etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery.
This uncontrolled clinical trial study was conducted on 50 patients suffering from mild to moderate allergic conjunctivitis  attending the Eye OPD of Government Medical College, Jammu between October 2017 and July 2018 who were receiving treatment in the form of steroid (Loteprednol
0.5%) eye drops and had shown improvement with control of both signs as well as symptoms of allergy.
Comparison of ketorolac tromethamine, diclofenac sodium and loteprednol
etabonate in an animal model of ocular inflammation.
Further, danazol and minocycline (oral medications) and loteprednol
(modified topical drugs) require daily administration, thus decreasing the necessity of patients to visit physicians .
Both groups were administered the same postoperative medication regimen; they were given Moxifloxacin 0.5% eye drops (Vigamox, Alcon) four times a day for two week, topical loteprednol
(Lotemax ophthalmic suspension, Bausch and Lomb) 4 times a day in tapering doses for 4 weeks, and topical artificial tear supplements four times a day for one month.
Advances in corticosteroid therapy for ocular inflammation: Loteprednol